Showing results (221-230 of 277) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 TrialPhilip C Schouten, Lisa Richters, Daniel J Vis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III TrialJacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2023
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian CarcinomasKarolin Heinze, Evan S Cairns, Shelby Thornton, et al.
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK UterusDominik Denschlag, Bastian Czogalla, Florian Heitz, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Geburtshilfe Und Frauenheilkunde|December 9, 2020
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?Linn Woelber, Mareike Bommert, Katharina Prieske, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 21, 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, et al.
Journal of the National Cancer Institute|April 25, 2026
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)Florence Joly, Amélie Anota, Sylvie Chabaud, et al.
European Journal of Cancer (Oxford, England : 1990)|November 13, 2016
Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter studyLinn Woelber, Lis-Femke Griebel, Christine Eulenburg, et al.
Cell Reports. Medicine|December 20, 2023
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profilesChristian Pozzorini, Gregoire Andre, Tommaso Coletta, et al.
Pageof 28